Market size, growth to 2033 and clinical trials, side by side.
The US is the bigger Anti-Depressants Drugs market: $7.6 Bn against $1.4 Bn in 2023, about 5.3 times as large.
Canada grows faster: 2.7% a year, against 0.7%. The gap still grows from $6.1 Bn to $6.2 Bn by 2033.
Clinical research: 936 active trials in the US, 170 in Canada.
| Measure | ||
|---|---|---|
| Market size, 2023 | $7.6 Bn | $1.4 Bn |
| Market size, 2033 projected | $8.1 Bn | $1.9 Bn |
| Growth a year (CAGR) | 0.7% | 2.7% |
| Money added, 2023–2033 | $547 Mn | $440 Mn |
| Share of the world market | 42% | 8% |
| Size rank of 24 countries | #1 | #3 |
| Market per person, 2023 | $22 | $35 |
| Active clinical trials | 936 | 170 |
| Full report | US report | Canada report |
US Canada · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
The US is the bigger Anti-Depressants Drugs market: $7.6 Bn against $1.4 Bn in 2023, about 5.3 times as large.
Canada grows faster: 2.7% a year, against 0.7%. The gap still grows from $6.1 Bn to $6.2 Bn by 2033.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.